Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Bogazzi

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Journal of Endocrinological Investigation|April 2, 2009
Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunctionM L Tanda, V Lombardi, M Genovesi, et al.
The New England Journal of Medicine|January 8, 1998
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathyL Bartalena, C Marcocci, F Bogazzi, et al.
Journal of Endocrinological Investigation|July 15, 2006
Myocardial systolic strain abnormalities in patients with acromegaly: a prospective color Doppler imaging studyV Di Bello, F Bogazzi, A Di Cori, et al.
Journal of Endocrinological Investigation|February 9, 2017
Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|June 23, 2009
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegalyG Lombardi, F Minuto, G Tamburrano, et al.
Journal of Endocrinological Investigation|June 27, 2012
Ectopic expression of FSH receptor isoforms in neoplastic but not in endothelial cells from pancreatic neuroendocrine tumorsC Sardella, D Russo, F Raggi, et al.
Journal of Endocrinological Investigation|December 30, 2017
Correction to: Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|April 1, 2022
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDYS Grottoli, A Bianchi, F Bogazzi, et al.
European Journal of Endocrinology|November 13, 2013
Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patientsM Filopanti, A M Barbieri, G Mantovani, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2011
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter studyM Filopanti, L Olgiati, G Mantovani, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Journal of Endocrinological Investigation|April 2, 2009
Plasma total and acylated Ghrelin concentrations in patients with clinical and subclinical thyroid dysfunctionM L Tanda, V Lombardi, M Genovesi, et al.
The New England Journal of Medicine|January 8, 1998
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathyL Bartalena, C Marcocci, F Bogazzi, et al.
Journal of Endocrinological Investigation|July 15, 2006
Myocardial systolic strain abnormalities in patients with acromegaly: a prospective color Doppler imaging studyV Di Bello, F Bogazzi, A Di Cori, et al.
Journal of Endocrinological Investigation|February 9, 2017
Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|June 23, 2009
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegalyG Lombardi, F Minuto, G Tamburrano, et al.
Journal of Endocrinological Investigation|June 27, 2012
Ectopic expression of FSH receptor isoforms in neoplastic but not in endothelial cells from pancreatic neuroendocrine tumorsC Sardella, D Russo, F Raggi, et al.
Journal of Endocrinological Investigation|December 30, 2017
Correction to: Pegvisomant in acromegaly: an updateA Giustina, G Arnaldi, F Bogazzi, et al.
Journal of Endocrinological Investigation|April 1, 2022
Are there country-specific differences in the use of pegvisomant for acromegaly in clinical practice? An analysis from ACROSTUDYS Grottoli, A Bianchi, F Bogazzi, et al.
European Journal of Endocrinology|November 13, 2013
Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patientsM Filopanti, A M Barbieri, G Mantovani, et al.
The Journal of Clinical Endocrinology and Metabolism|December 14, 2011
Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter studyM Filopanti, L Olgiati, G Mantovani, et al.
Pageof 11